348 results on '"Afzali, Anita"'
Search Results
52. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence with Inflammatory Bowel DiSease Therapy—ASSIST Study: A Randomized Controlled Trial (Preprint)
53. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
54. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
55. Reply
56. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.
57. 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
58. Su1505: IMPACT OF CONCOMITANT PROTON PUMP INHIBITOR AND ADVANCED THERAPY USE ON HEALTH OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
59. Su1510: IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS
60. Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
61. Tu1472: RAPIDITY OF OZANIMOD-INDUCED SYMPTOMATIC RESPONSE AND REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PERIOD OF TRUE NORTH
62. Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
63. 969: RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
64. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
65. Impact of Cannabis Use on Inpatient Inflammatory Bowel Disease Outcomes in 2 States Legalizing Recreational Cannabis
66. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES
67. Su1792 EFFICACY OUTCOMES OF PLACEBO MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RESPONDED TO PLACEBO INDUCTION THERAPY: RESULTS FROM THE PHASE 3 COMMAND STUDY
68. Su1797 ETRASIMOD SHOWS LOW RISK OF ADVERSE EVENTS FOLLOWING CONCOMITANT USE WITH OPIOIDS OR ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
69. IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS
70. Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis
71. S931 Initial 8-week Therapy with Tofacitinib in Moderate-to-Severe Ulcerative Colitis in a Real World Prospective Multicenter Study (TOUR)
72. S748 Early PRO-2 Symptom Remission Following Guselkumab Induction Treatment: Results Through Week 12 of the Phase 2 GALAXI 1 Study
73. S749 Unmet Needs in Advanced Therapy-Naïve and Advanced Therapy-experienced Moderate-to-Severe Ulcerative Colitis Patients in the United States
74. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease
75. Social Media—The Next Glass Ceiling?
76. Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
77. Impact of rapid infliximab infusions on access at a large academic tertiary medical center
78. 611 THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE
79. Su461 SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB
80. 460 RAPID INDUCTION EFFECTS OF OZANIMOD ON CLINICAL SYMPTOMS AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PHASE OF TRUE NORTH
81. Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
82. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey
83. Predicting Suboptimal Transitions in Adolescents With Inflammatory Bowel Disease
84. 63 TRENDS IN RACIAL DISPARITIES IN SURGICAL CARE FOR IBD PATIENTS
85. Tu1799 ASSOCIATION OF EARLY CLINICAL EFFICACY FACTORS WITH 1-YEAR RESPONSE AND REMISSION TO TOFACITINIB IN MODERATE TO SEVERE ULCERATIVE COLITIS IN A REAL WORLD PROSPECTIVE MULTICENTER STUDY (TOUR)
86. Tu1725 EFFECTS OF OZANIMOD ON HISTOLOGIC REMISSION AND MUCOSAL HEALING OVER 3 YEARS OF CONTINUOUS TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
87. Tu1707 CORTICOSTEROID-FREE CLINICAL REMISSION RATES WITH GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2B GALAXI 1 STUDY
88. Su1023 MOVING THE NEEDLE FOR WOMEN IN GASTROENTEROLOGY: ACQUIRING LEADERSHIP SKILLS FOR CAREER GROWTH!
89. 950 LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
90. Excellent Posttransplant Survival for Patients with Nonalcoholic Steatohepatitis in the United States
91. S0668 Time to Improvement in Patient-Reported Outcomes With Tofactinib in Ulcerative Colitis: Initial Results From a Real World Prospective Multicenter Study (TOUR)
92. S0776 Inpatient Outcomes in Inflammatory Bowel Disease Patients With Non-Alcoholic Fatty Liver Disease
93. Su1507 ESTABLISHING A PEDIATRIC TO ADULT (P2A) TRANSITION FOR PANCREATIC DISEASE: CONNECT-ING INSPPIRE AND PROCEED
94. Sa1854 WOMEN WITH IMMUNE MEDIATED INFLAMMATORY DISEASES WHO USE BIOLOGICS DURING PREGNANCY HAVE A HIGHER RISK FOR POSTPARTUM FLARE
95. Su2069 ELECTIVE VS UNPLANNED SURGICAL INTERVENTIONS FOR BOWEL OBSTRUCTION IN CROHN'S DISEASE: IS THERE A ROLE FOR PREEMPTIVE SURGICAL INTERVENTION?
96. 123 PATIENT AND PHYSICIAN PERSPECTIVES ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: ROLE OF STEROIDS IN THE CONTEXT OF BIOLOGIC THERAPY
97. Mo1892 PREDICTING SUB-OPTIMAL TRANSITIONS IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASES
98. Sa1745 IMPACT OF A PATIENT SUPPORT PROGRAM ON INFLAMMATORY BOWEL DISEASE-RELATED HOSPITALIZATION IN PATIENTS TREATED WITH ADALIMUMAB
99. Su1823 PATIENT AND PHYSICIAN PERSPECTIVES ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: DISEASE REMISSION AND DURABILITY OF TREATMENT
100. 241 COMBINATION OF SERUM ENDOSCOPIC HEALING INDEX AND THERAPEUTIC DRUG MONITORING ALLOWS FOR NON-INVASIVE TIGHT DISEASE MANAGEMENT IN ADULT PATIENTS WITH CROHN'S DISEASE TREATED WITH ANTI-TUMOR NECROSIS FACTOR THERAPY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.